Navigation Links
Novartis Consumer Health Inc. Issues Voluntary Nationwide Recall of Certain Over-the-Counter Products Due to Potential Presence of Foreign Tablets or Chipped or Broken Tablets or Gelcaps
Date:1/8/2012

eventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

Novartis Media Relations 

 Julie MasowNovartis Corporation

+1 212 830 2465 (direct)

+1 862 579 8456 (mobile)

julie.masow@novartis.com

 

Pamela McKinlayNovartis Consumer Health, Inc.

+1 973 503 7337(direct)

+1 862 221 0151(mobile)

pamela.mckinlay@novartis.com

 

e-mail: us.mediarelations@novartis.com Milicent BrooksNovartis Consumer Health, Inc.

+1 973 503 7483(direct)

+1 973 479 2078 (mobile)

milicent.brooks@novartis.com

 For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.MaterialMaterial descriptionUPC CodeUCC CodeNDC CodeQuantity Returned100007332

Bufferin® Extra Strength Tablets 130CT 

300672065131

103
'/>"/>

SOURCE Novartis Consumer Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
2. New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
3. Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
4. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
5. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
6. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
7. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
8. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
9. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
10. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
11. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Medical Oxygen Systems - Global Strategic Business ... report analyzes the worldwide markets for Medical Oxygen Systems ... Liquid Oxygen Systems, Oxygen Cylinders & Regulators, and Oxygen ... the US, Canada , ...
(Date:4/17/2015)... Steven Rash , the CEO of Algae International Group, ... Seed & Oil Company, presented the Company,s latest developments ... York City.  Mr. Rash,s presentation featured the Company,s Product ... Company has recently announced the Dube Hemp Energy ... the EpiVape , and Hempster Clothing .  ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has announced ... in 2014 - a Perspective of Diabetes Patient Groups ... This independent study, funded by the author, represents ... in diabetes on the corporate reputation of 14 individual ... whole) in 2014. The results from the respondent diabetes ...
Breaking Medicine Technology:Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
(Date:4/18/2015)... 2015 Insuranceautoquote.info has released a new ... insurance quotes . , Clients can review important ... The online environment provides important advantages for clients who ... Drivers who do not have coverage for their vehicles ... season, day or hour. Many agencies offer important discounts ...
(Date:4/18/2015)... 18, 2015 Thousand of DePuy Pinnacle ... of individuals who were allegedly harmed by a metal-on-metal ... forward in the U.S. District Court, Northern District of ... Court has amended an earlier Case Management Order to ... things, the new amendment permits the claims of up ...
(Date:4/18/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Physical Therapy Association Annual Conference to be held ... Greenville, SC. , The SCAPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... 2015 Riviera Magazine has ... of the Gallery of Cosmetic Surgery in Newport ... experts. The publication focused on his expertise in ... fat grafting, eyelid surgery, laser resurfacing and rhinoplasty. , ... has resulted in thousands of satisfied patients across ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... cerebrovascular disease , MONDAY, Dec. 10 (HealthDay News) -- ... for mild cognitive impairment, says a study by researchers ... City. , Mild cognitive impairment, which causes learning and ... years, particularly as a means of identifying the early ...
... team of researchers from the University of Pennsylvania School ... in the immune system process that fights infection yet, ... tissue., The Penn team, led by Christopher Hunter, chair ... identified the pathways that lead to the production of ...
... Although psychiatrists are among the least religious physicians, they ... and spiritual dimensions of their patients, according to survey ... Journal of Psychiatry. , Ever since Freud described religious ... been tension and at times hostility between religion and ...
... problems with Prilosec and Nexium , , MONDAY, Dec. ... of the popular heartburn drugs Prilosec and Nexium found ... Monday. , The announcement followed a three-month safety review ... preliminary studies. But detailed data from both studies, plus ...
... Dec. 10 JPMorgan,s Annual,Healthcare Conference, which celebrates ... 7-10 at the Westin St. Francis Hotel in ... largest, will feature,presentations from approximately 300 companies, both ... This year,s event will include,panel discussions with leading ...
... mg, * 53% of Patients Treated with 90 mg Dose ... in the Risk of Death ... Compared to Non-responders, ATLANTA, Dec. 10 Pharmion ... data,from the Phase 1/2 study investigating the combined use of MGCD0103, a,novel, ...
Cached Medicine News:Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Researchers led by Penn vet uncover the delicate protein balance behind the immune system response 2Health News:Psychiatrists: Least religious but most interested in patients' religion 2Health News:Psychiatrists: Least religious but most interested in patients' religion 3Health News:Psychiatrists: Least religious but most interested in patients' religion 4Health News:FDA Confirms No Heart Risk From Heartburn Drugs 2Health News:FDA Confirms No Heart Risk From Heartburn Drugs 3Health News:JPMorgan's 26th Annual Healthcare Conference Media Advisory 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: